Literature DB >> 10664321

Prospective study of preincisional intraparietal single-dose ceftriaxone in reducing postoperative wound infection in type I and II diabetic patients.

I Petrakis1, C Gonianakis, N Vrachassotakis, A Tsatsakis, I S Vallilakis, G Chalkiadakis.   

Abstract

The risk of wound contamination in diabetic patients after abdominal operations is well known. Preincisional intraparietal injection of antibiotics is used for the prophylaxis of postoperative surgical infections. Whether topically injected antibiotics remain primarily in the surgical wound or are systematically absorbed is uncertain, however. The pharmacokinetics of a preincisional, intraparietal injection of 2 g ceftriaxone was studied in 50 consecutive diabetic (type I and II) patients undergoing abdominal surgery, with determination of serum, wound tissue, and wound fluid antibiotic concentrations. Preincisional intraparietal injection of ceftriaxone resulted in high antibiotic concentrations in the wound fluid. The highest plasma concentrations were achieved at 1.5 h (98.45 microg/ml, SD = 14.54). Plasma concentrations exceeded the minimal inhibitory concentrations of most aerobic gram positive and gram negative organisms with the exception of Pseudomonas aeruginosa, Acinetobacter species, and Streptococcus faecalis for 24 h (10.35 microg/ml, SD = 4.10). No long-lasting or general complications arose in any of the diabetic patients. Our results suggest that preincisional intraparietal administration of ceftriaxone for prophylaxis of wound sepsis in diabetic patients with high risk of infection is effective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10664321     DOI: 10.1007/s005920050160

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  1 in total

1.  Antimicrobial resistance development following surgical site infections.

Authors:  Daniela Călina; Anca Oana Docea; Lucica Rosu; Ovidiu Zlatian; Alexandra Floriana Rosu; Florin Anghelina; Otilia Rogoveanu; Andreea Letiția Arsene; Alina Crenguța Nicolae; Cristina Manuela Drăgoi; John Tsiaoussis; Aristides M Tsatsakis; Demetrios A Spandidos; Nikolaos Drakoulis; Eliza Gofita
Journal:  Mol Med Rep       Date:  2016-12-13       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.